Resumen de Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
M. Sánchez Cánovas, David Fernández Garay, Evdochia Adoamnei, Esperanza Guirao García, Javier López Robles, Diego Cacho Lavín, Eva Martínez de Castro, Begoña Campos Balea, Alberto Garrido Fernández, Isaura Fernández Pérez, Asia Ferrández, Noelia Suarez, Teresa Quintanar, Miriam Lobo de Mena, Laura Rodríguez Lajusticia, David Gutiérrez Abad, Ana Manuela Martín Fernández de Soignie, Silvia García Adrián, Ana Isabel Ferrer Pérez, María Jesús Delgado Heredia, Amelia Muñoz Lerma, Raquel Luque Caro, Manuel Mazariegos Rubí, Ana Belen Rupérez Blanco, Ignacio García Escobar, Jaime Mendiola, Andrés Jesús Muñoz Martín
Purpose Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice.
Methods/patients Retrospective, multicenter study promoted by the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM). Individuals with kidney or bladder cancer who initiated ICI between 01/01/2015 and 12/31/2020 were recruited. Minimum follow-up was 6 months (except in cases of demise). The primary objective was to calculate the incidence of ICI-associated VTE/AT and secondary objectives included to analyze their impact on survival and identify variables predictive of VTE/AT.
Results 210 patients with kidney cancer were enrolled. The incidence of VTE/AT during follow-up (median 13 months) was 5.7%. Median overall survival (OS) was relatively lower among subjects with VTE/AT (16 months, 95% CI 0.01–34.2 vs. 27 months, 95% CI 22.6–31.4; p = 0.43). Multivariate analysis failed to reveal predictive variables for developing VTE/ AT.
197 patients with bladder were enrolled. There was a 9.1% incidence rate of VTE/AT during follow-up (median 8 months). Median OS was somewhat higher in patients with VTE/AT (28 months, 95% CI 18.4–37.6 vs 25 months, 95% CI 20.7–29.3; p = 0.821). Serum albumin levels < 3.5 g/dl were predictive of VTE/ AT (p < 0.05).
Conclusions There appears to be no association between developing VTE/AT and ICI use in patients with renal or bladder cancer. Serum albumin levels are a predictive factor in individuals with bladder cancer.
